Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report

BACKGROUND: Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of non-Hodgkin’s lymphoma, which has an aggressive clinical course and an extremely poor prognosis. Chidamide is a novel, orally active, benzamide-type histone deacetylase (HDAC) inhibitor that has been used for peripheral T-cell ly...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xing-Tong, Guo, Wei, Sun, Mo, Han, Wei, Du, Zhong-Hua, Wang, Xiu-Xiu, Du, Bei-Bei, Bai, Ou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385602/
https://www.ncbi.nlm.nih.gov/pubmed/32775395
http://dx.doi.org/10.12998/wjcc.v8.i14.3122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385602/
https://www.ncbi.nlm.nih.gov/pubmed/32775395
http://dx.doi.org/10.12998/wjcc.v8.i14.3122

Ejemplares similares